WuXi AppTec, a global provider of R&D and manufacturing enabling services in the pharma/biopharma and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies.   OXGENE will become a fully-owned subsidiary of WuX...